Teleflex to Separate into Two Companies

February 27, 2025—Teleflex Incorporated announced a plan to separate the company’s urology, acute care, and original equipment manufacturer (OEM) businesses into a new, independent, publicly traded company: NewCo. Teleflex RemainCo will consist of Teleflex’s vascular access, interventional, and surgical businesses.

According to Teleflex, the separation will position each company to accelerate its growth profile with a simplified operating model, streamlined manufacturing footprint, better allocation of resources, and increased management focus.

The Teleflex Board of Directors authorized company management to pursue the plan after a comprehensive business portfolio evaluation, noted the press release.

The transaction, which is expected to be completed in 2026, will be conducted through a distribution of newly issued shares of NewCo to shareholders that is tax-free for United States tax purposes, advised Teleflex.

The press release stated that Liam Kelly will continue to lead RemainCo as Chairman, President, and Chief Executive Officer. Teleflex intends to initiate an executive search for key management positions at NewCo, and the NewCo Board of Directors, management, and headquarters will be announced as they are finalized, stated Teleflex.

On February 27, Teleflex announced a definitive agreement to acquire substantially all of the vascular intervention business of Biotronik for approximately €760 million. That transaction is expected to be completed by the end of the third quarter of 2025. The acquired vascular intervention business will be added to Teleflex’s interventional portfolio, stated the company.